News about Global Pharma

ProRx Pharma Expands Production to Meet Demand for Drugs on FDA Shortage List

ProRx is currently expanding its operations to a total of 6,888 square feet, doubling its existing 3,400-square-foot pharmaceutical and manufacturing facility.

Global Pharma | 01/03/2025 | By Aishwarya |  576

USFDA Approves Fapon Biopharma's Investigational New Drug (IND) Application for FP008

Fapon Biopharma announced that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for FP008, its first-in-class immunocytokine designed to address the unmet need in patients with solid tumors refractory to anti-PD-1 therapy.

Global Pharma | 28/02/2025 | By Manvi |  353

Senores Pharmaceuticals Commence Operations at Greenfield API Facility at Mehsana, Gujarat

Senores Pharmaceuticals Ltd. has inaugurated and commenced manufacturing activities at its greenfield API manufacturing facility in Mehsana. This is Senores’ second API manufacturing facility and has an installed capacity of ~100 Metric Tons per Annum.

Global Pharma | 28/02/2025 | By Manvi |  443

Systech Develops UniSecure artAI for Life Sciences and Pharmaceutical Industries

artAI uses advanced machine vision and machine learning to create a digital blueprint of key packaging artwork features, enabling precise verification and quality inspection through pattern recognition.

Global Pharma | 28/02/2025 | By Aishwarya |  491

Zydus Lifesciences to Launch Protection Against New Strain of Influenza Virus

The Quadrivalent Inactivated Influenza vaccine has been developed at the Vaccine Technology Centre (VTC) in Ahmedabad which has proven capabilities in researching, developing, and manufacturing of safe and efficacious vaccines.

Global Pharma | 28/02/2025 | By Aishwarya |  408

Nxera Pharma Assigns Japan Rights to Cenerimod for Autoimmune Diseases to Viatris

Nxera will receive an upfront payment of USD 10 million from Viatris and is eligible to receive a milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales should it be commercialized in the assigned territories.

Global Pharma | 28/02/2025 | By Aishwarya |  543

Venus Remedies Bags Exclusive Licensing Rights for MET-X from Infex Therapeutics

This strategic collaboration grants Venus Remedies the rights to spearhead clinical development, regulatory approvals, and commercialization of MET-X in India, focusing on its integration with meropenem to tackle infections resistant to conventional treatments.

Global Pharma | 28/02/2025 | By Aishwarya |  569

ProductLife Group Acquires Herax Life Science to Boost R&D Business

This acquisition unites HERAX Life Science and PLG under a shared commitment to accelerate drug development, streamline clinical trials, and ensure the highest standards of safety and compliance.

Global Pharma | 27/02/2025 | By Aishwarya |  241

Glenmark Pharmaceuticals Launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial in US

Glenmark Pharmaceuticals Inc., USA, has launched Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial, securing 180 days of CGT exclusivity.

Global Pharma | 27/02/2025 | By Manvi |  373

Lupin Secures Place in S&P Global Sustainability Yearbook 2025

Lupin Ltd. has been included in the S&P Global Sustainability Yearbook 2025 for the second consecutive year, recognising its strong commitment to sustainability and improved Corporate Sustainability Assessment (CSA) score.

Global Pharma | 27/02/2025 | By Manvi |  518